These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 16669852)
1. Prescribing behaviour according to Dutch and European guidelines on the management of hypercholesterolaemia (1992-1999). Mantel-Teeuwisse AK; Klungel OH; Hofman A; Verschuren WM; Trienekens PH; Porsius AJ; Stricker BH; de Boer A Br J Clin Pharmacol; 2006 May; 61(5):592-600. PubMed ID: 16669852 [TBL] [Abstract][Full Text] [Related]
2. Drug costs associated with non-adherence to cholesterol management guidelines for primary prevention of cardiovascular disease in an elderly population: the Rotterdam study. Gumbs PD; Verschuren WM; Mantel-Teeuwisse AK; de Wit AG; Hofman A; Trienekens PH; Stricker BH; de Boer A; Klungel OH Drugs Aging; 2006; 23(9):733-41. PubMed ID: 17020397 [TBL] [Abstract][Full Text] [Related]
3. Time to improve statin prescription guidelines in low-risk patients? Balder JW; de Vries JK; Mulder DJ; Kamphuisen PW Eur J Prev Cardiol; 2017 Jul; 24(10):1064-1070. PubMed ID: 28429651 [TBL] [Abstract][Full Text] [Related]
4. Increases in statin eligibility to reduce cardiovascular risk according to the 2013 ACC/AHA cholesterol guidelines in the Africa Middle East region: a sub-analysis of the Africa Middle East Cardiovascular Epidemiological (ACE) study. Hamoui O; Omar MI; Raal FJ; Rashed W; Kane A; Alami M; Abreu P; Mashhoud W; Alsheikh-Ali AA BMC Cardiovasc Disord; 2019 Mar; 19(1):61. PubMed ID: 30876390 [TBL] [Abstract][Full Text] [Related]
6. Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey. Krempf M; Simpson RJ; Ramey DR; Brudi P; Giezek H; Tomassini JE; Lee R; Farnier M Lipids Health Dis; 2015 May; 14():45. PubMed ID: 25985907 [TBL] [Abstract][Full Text] [Related]
7. Effectiveness of two statin prescribing strategies with respect to adherence and cardiovascular outcomes: observational study. Wei L; MacDonald TM; Watson AD; Murphy MJ Pharmacoepidemiol Drug Saf; 2007 Apr; 16(4):385-92. PubMed ID: 16998946 [TBL] [Abstract][Full Text] [Related]
8. Lipid-modifying therapy and attainment of cholesterol goals in Hungary: the return on expenditure achieved for lipid therapy (REALITY) study. Paragh G; Márk L; Zámolyi K; Pados G; Ofner P Clin Drug Investig; 2007; 27(9):647-60. PubMed ID: 17705573 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of Statin Prescribing for Secondary Prevention in Primary Care Following New Guideline Recommendations. Zupec JF; Marrs JC; Saseen JJ Ann Pharmacother; 2016 Jan; 50(1):17-21. PubMed ID: 26416950 [TBL] [Abstract][Full Text] [Related]
10. Cholesterol treatment and changes in guidelines in an academic medical practice. Schoen MW; Salas J; Scherrer JF; Buckhold FR Am J Med; 2015 Apr; 128(4):403-9. PubMed ID: 25460526 [TBL] [Abstract][Full Text] [Related]
11. Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation. Ara R; Tumur I; Pandor A; Duenas A; Williams R; Wilkinson A; Paisley S; Chilcott J Health Technol Assess; 2008 May; 12(21):iii, xi-xiii, 1-212. PubMed ID: 18485273 [TBL] [Abstract][Full Text] [Related]
12. [Lipid-lowering therapy and patient adherence in the MULTI GAP 2013 trial]. Simonyi G Orv Hetil; 2014 Apr; 155(17):669-75. PubMed ID: 24755449 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Prosser LA; Stinnett AA; Goldman PA; Williams LW; Hunink MG; Goldman L; Weinstein MC Ann Intern Med; 2000 May; 132(10):769-79. PubMed ID: 10819699 [TBL] [Abstract][Full Text] [Related]
14. Sociodemographic and diagnostic characteristics of prescribing a second-line lipid-lowering medication: ezetimibe used as initial medication, switch from statins, or add-on medication. Wallach-Kildemoes H; Hansen EH Eur J Clin Pharmacol; 2015 Oct; 71(10):1245-54. PubMed ID: 26227068 [TBL] [Abstract][Full Text] [Related]
15. Initiation Patterns of Statins in the 2 Years After Release of the 2013 American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Management Guideline in a Large US Health Plan. Olufade T; Zhou S; Anzalone D; Kern DM; Tunceli O; Cziraky MJ; Willey VJ J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28473405 [TBL] [Abstract][Full Text] [Related]
16. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice. Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658 [TBL] [Abstract][Full Text] [Related]
17. Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia. Cook JR; Yin D; Alemao E; Drummond M Pharmacoeconomics; 2004; 22 Suppl 3():37-48. PubMed ID: 15669152 [TBL] [Abstract][Full Text] [Related]
18. Impact of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines on the prescription of high-intensity statins in patients hospitalized for acute coronary syndrome or stroke. Valentino M; Al Danaf J; Panakos A; Ragupathi L; Duffy D; Whellan D Am Heart J; 2016 Nov; 181():130-136. PubMed ID: 27823684 [TBL] [Abstract][Full Text] [Related]
19. Audit-based education to reduce suboptimal management of cholesterol in primary care: a before and after study. de Lusignan S; Belsey J; Hague N; Dhoul N; van Vlymen J J Public Health (Oxf); 2006 Dec; 28(4):361-9. PubMed ID: 17038329 [TBL] [Abstract][Full Text] [Related]
20. [Cholesterol-lowering therapy; a recommendation from the Health Council]. Simoons ML Ned Tijdschr Geneeskd; 2000 Dec; 144(51):2442-4. PubMed ID: 11151651 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]